Harold C. Neu

Harold C. Neu's AcademicInfluence.com Rankings

Harold C. Neu

Biology

#1885

World Rank

#3054

Historical Rank

Microbiology

#36

World Rank

#52

Historical Rank

biology Degrees

Harold C. Neu

Philosophy

#1829

World Rank

#3242

Historical Rank

Logic

#326

World Rank

#655

Historical Rank

philosophy Degrees

Download Badge

Biology
Philosophy

Harold C. Neu's Degrees

PhD Microbiology Stanford University
Doctorate Medicine Stanford University

Why Is Harold C. Neu Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Harold C. Neu's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The Crisis in Antibiotic Resistance (1992) (2777)
The release of enzymes from Escherichia coli by osmotic shock and during the formation of spheroplasts. (1965) (1331)
Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria (1984) (349)
The new beta-lactamase-stable cephalosporins. (1982) (278)
Deaths from nosocomial infections: experience in a university hospital and a community hospital. (1980) (277)
INFECTIVE ENDOCARDITIS—AN EVOLVING DISEASE: A Review of Endocarditis at The Columbia‐Presbyterian Medical Center, 1968–1973 (1978) (269)
Clavulanic Acid, a Novel Inhibitor of β-Lactamases (1978) (203)
The Nephrotoxicity of Antimicrobial Agents (1977) (201)
Digoxin-inactivating bacteria: identification in human gut flora. (1983) (201)
Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group. (1993) (189)
Infective endocarditis at the Presbyterian Hospital in New York City from 1938-1967. (1971) (177)
Piperacillin, a new penicillin active against many bacteria resistant to other penicillins (1978) (171)
HR 756, a New Cephalosporin Active Against Gram-Positive and Gram-Negative Aerobic and Anaerobic Bacteria (1979) (171)
Quinolone antimicrobial agents. (1992) (171)
Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. (1996) (160)
ORAL CIPROFLOXACIN THERAPY OF INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA (1986) (155)
SEPTICEMIA WITH NON-TYPHOID SALMONELLA (1974) (148)
In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim (1983) (147)
The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. (1981) (144)
National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. (1998) (144)
Cefamandole, a Cephalosporin Antibiotic with an Unusually Wide Spectrum of Activity (1974) (143)
Bone and joint infections due to Salmonella. (1978) (143)
The 5'-nucleotidase of Escherichia coli. I. Purification and properties. (1967) (135)
Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin (1981) (134)
NUCLEOTIDE SEQUENCE ANALYSIS OF POLYRIBONUCLEOTIDES BY MEANS OF PERIODATE OXIDATION FOLLOWED BY CLEAVAGE WITH AN AMINE. (1964) (130)
Beta-Lactamase Stability of HR 756, a Novel Cephalosporin, Compared to That of Cefuroxime and Cefoxitin (1978) (128)
Antibacterial Activity of a New 1-Oxa Cephalosporin Compared with That of Other β-Lactam Compounds (1979) (123)
Comparative Activity and β-Lactamase Stability of Cefoperazone, a Piperazine Cephalosporin (1979) (123)
THE RELEASE OF RIBONUCLEASE INTO THE MEDIUM WHEN ESCHERICHIA COLI CELLS ARE CONVERTED TO SPEROPLASTS. (1964) (123)
On the surface localization of enzymes in E. coli. (1964) (121)
beta-Lactam antibiotics: structural relationships affecting in vitro activity and pharmacologic properties. (1986) (121)
Release of Surface Enzymes in Enterobacteriaceae by Osmotic Shock (1967) (119)
Histoplasmosis in patients with the acquired immune deficiency syndrome. (1986) (116)
Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability (1982) (115)
Bacterial resistance to fluoroquinolones. (1988) (114)
Relation of structural properties of beta-lactam antibiotics to antibacterial activity. (1985) (106)
NEPHROTOXICITY OF ANTIMICROBIAL AGENTS — SECOND OF THREE PARTS (1977) (106)
A critical review of the dosage of teicoplanin in Europe and the USA. (1994) (105)
The development of macrolides: clarithromycin in perspective. (1991) (105)
In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone (1986) (104)
Late hematogenous infection of total joint replacement. (1980) (102)
Azlocillin and Mezlocillin: New Ureido Penicillins (1978) (100)
Primary cutaneous aspergillosis in six leukemic children. (1985) (100)
Antimicrobial activity and human pharmacology of amoxicillin. (1974) (95)
In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones (1988) (94)
Clinical microbiology of azithromycin. (1991) (93)
In vitro activity of chloramphenicol and thiamphenicol analogs (1980) (93)
In vitro activity of the new fluoroquinolone CP-99,219 (1994) (92)
Antibacterial activity of ceftizoxime, a beta-lactamase-stable cephalosporin (1980) (90)
In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim (1982) (90)
Cefuroxime, a Beta-Lactamase-Resistant Cephalosporin with a Broad Spectrum of Gram-Positive and -Negative Activity (1978) (85)
Direct detection and amplification of Helicobacter pylori ribosomal 16S gene segments from gastric endoscopic biopsies. (1990) (84)
Gastrointestinal histoplasmosis (2005) (81)
Safety of cefepime: a new extended-spectrum parenteral cephalosporin. (1996) (80)
Expanding indications for the new macrolides, azalides, and streptogramins. (1997) (80)
Ciprofloxacin therapy in cystic fibrosis. (1987) (79)
Tobramycin: an overview. (1976) (78)
Synergy of Mecillinam, a Beta-Amidinopenicillanic Acid Derivative, Combined with Beta-Lactam Antibiotics (1976) (78)
Obstructive respiratory dysfunction in parkinsonian patients. (2015) (78)
Mecillinam, a Novel Penicillanic Acid Derivative with Unusual Activity Against Gram-Negative Bacteria (1976) (77)
Pharmacokinetics of cefotaxime (1979) (77)
Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin (1984) (76)
Structure-Activity Relations of New β-Lactam Compounds and in Vitro Activity Against Common Bacteria (1983) (75)
The role of Pseudomonas aeruginosa in infections. (1983) (74)
The release of ribonuclease into the medium when E. coli cells are converted to spheroplasts. (1964) (74)
In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria (1984) (73)
In vitro activity of teichomycin compared with those of other antibiotics (1983) (73)
The pharmacokinetic and bactericidal characteristics of oral cefixime (1985) (72)
INTERACTION BETWEEN MOXALACTAM AND ALCOHOL (1980) (72)
The Aminoglycosides: Microbiology, Clinical Use, and Toxicology (1982) (71)
Cefaclor: In Vitro Spectrum of Activity and Beta-Lactamase Stability (1978) (70)
Antimicrobial resistance and R-factor transfer among isolates of Salmonella in the northeastern United States: a comparison of human and animal isolates. (1975) (70)
In Vitro Studies of Tobramycin, an Aminoglycoside Antibiotic (1972) (70)
Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. (1993) (69)
In vitro activity and beta-lactamase stability of a new carbapenem, SM-7338 (1989) (68)
The emergence of bacterial resistance and its influence on empiric therapy. (1983) (67)
The in vitro activity, human pharmacology, and clinical effectiveness of new beta-lactam antibiotics. (1982) (67)
Antibacterial activity of desacetylcefotaxime alone and in combination with cefotaxime. (1982) (67)
Effect of N-acetylcysteine on antibiotic activity and bacterial growth in vitro (1977) (66)
In Vitro Study of Netilmicin Compared with Other Aminoglycosides (1976) (66)
Testing the physician's knowledge of antibiotic use: Self-assessment and learning via videotape. (1975) (65)
The in-vitro activity and β-lactamase stability of carumonam (1986) (65)
CLINICAL USE OF THE QUINOLONES (1987) (63)
Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin. (1977) (63)
Synergy of fluoroquinolones with other antimicrobial agents. (1989) (62)
Ototoxicity of tobramycin: a clinical overview. (1976) (62)
Agents responsible for infection in chronic granulomatous disease of childhood. (1975) (60)
In vitro activity of sparfloxacin (1991) (60)
Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit beta-lactamases. (1985) (60)
SOME OBSERVATIONS ON THE "LATENT" RIBONUCLEASE OF ESCHERICHIA COLI. (1964) (60)
Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin, and daptomycin (1991) (60)
Mupirocin treatment of nasal staphylococcal colonization. (1992) (58)
J774 macrophages secrete antibiotics via organic anion transporters. (1992) (58)
Carbenicillin: clinical and laboratory experience with a parenterally administered penicillin for treatment of Pseudomonas infections. (1969) (57)
Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa (1982) (57)
The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination. (1992) (57)
Cefoxitin, a Semisynthetic Cephamycin Antibiotic: Antibacterial Spectrum and Resistance to Hydrolysis by Gram-Negative Beta-Lactamases (1974) (56)
A sulfone beta-lactam compound which acts as a beta-lactamase inhibitor. (1978) (56)
In vitro activity of S-ofloxacin (1989) (56)
Synergy of Azlocillin and Mezlocillin Combined With Aminoglycoside Antibiotics and Cephalosporins (1978) (55)
Dosage recommendations for teicoplanin. (1993) (55)
Necrotizing nocardial pneumonitis. (1967) (55)
Pharmacokinetics of ticarcillin in patients with abnormal renal function. (1976) (55)
Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin (1989) (54)
Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969) (1988) (53)
Antibacterial activity and beta-lactamase stability of temocillin (1982) (53)
In vitro activity of OPC-17116 (1992) (51)
Pharmacology of aztreonam after intravenous infusion (1983) (50)
The nephrotoxicity of antimicrobial agents Pt 3. (1977) (50)
Cephalosporin antibiotics as applied in surgery of bones and joints. (1984) (50)
Urinary tract infections. (1992) (49)
Streptococcus agalactiae (group B) endocarditis — A description of twelve cases and review of the literature (1987) (48)
New antibiotics: areas of appropriate use. (1987) (48)
The comparative beta-lactamase resistance and inhibitory activity of 1-oxa cephalosporin, cefoxitin and cefotaxime. (1979) (48)
Antibacterial activity of a monocyclic β-lactam SQ 26,776 (1981) (48)
The 5'-nucleotidase of Escherichia coli. II. Surface localization and purification of the Escherichia coli 5'-nucleotidase inhibitor. (1967) (47)
Comparative Inhibition of β-Lactamases by Novel β-Lactam Compounds (1979) (47)
In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents. (1985) (46)
Ticarcillin for treatment of serious infections with gram-negative bacteria. (1976) (46)
Clavulanic acid, a novel inhibitor of beta-lactamases. (1978) (45)
Clinical efficacy of ceftazidime. Treatment of serious infection due to multiresistant Pseudomonas and other gram-negative bacteria. (1984) (44)
A comparative study of ticarcillin plus tobramycin versus carbenicillin plus gentamicin for the treatment of serious infections due to gram-negative bacilli. (1978) (44)
Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. (1978) (44)
In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime. (1987) (43)
ALLERGIC CROSS-REACTIVITY OF TEICOPLANIN AND VANCOMYCIN (1986) (43)
Inactivation of digoxin by Eubacterium lentum, an anaerobe of the human gut flora. (1982) (43)
Oligonucleotide probe for detection and identification of Campylobacter pylori (1989) (43)
In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem (1986) (42)
Mecillinam--an amidino penicillin which acts synergistically with other beta-lactam compounds. (1977) (42)
Current mechanisms of resistance to antimicrobial agents in microorganisms causing infection in the patient at risk for infection. (1984) (42)
The inhibitory quotient. (1983) (42)
In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074) (1986) (41)
Carbapenems: special properties contributing to their activity. (1985) (41)
Surface Localization of Escherichia coli 5′-Nucleotidase by Electron Microscopy (1969) (41)
Shigella bacteremia in adults. (1986) (40)
A comparative study of the activity of cefamandole and other cephalosporins and analysis of the beta-lactamase stability and synergy of cefamandole with aminoglycosides. (1978) (40)
In vitro activity of cefquinome, a new cephalosporin, compared with other cephalosporin antibiotics. (1992) (40)
The surface localization of penicillinases in Escherichia coli and Salmonella typhimurium. (1968) (39)
Reduction in Tuberculin Skin-Test Conversions Among Medical House Staff Associated with Improved Tuberculosis Infection Control Practices (1997) (38)
The activity of BMY 28142 a new broad spectrum β-lactamase stable cephalosporin (1986) (38)
Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa. (1985) (38)
In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents (1986) (38)
Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis (1983) (38)
Antibacterial activity of coumermycin alone and in combination with other antibiotics (1984) (37)
Inactivation of beta-lactam antibiotics by Legionella pneumophila (1979) (37)
The in-vitro activity of a novel penem FCE 22101 compared to other beta-lactam antibiotics. (1985) (37)
Resistance to ciprofloxacin appearing during therapy. (1989) (37)
Quinolones: a new class of antimicrobial agents with wide potential uses. (1988) (37)
Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria (1987) (37)
Changing Mechanisms of Bacterial Resistance (1984) (36)
In Vitro Synergistic Effect of Netilmicin, a New Aminoglycoside Antibiotic (1976) (36)
Antibiotic-associated pseudomembranous colitis in children. (1979) (36)
Successful treatment of Pseudomonas cepacia endocarditis in a heroin addict with trimethoprim-sulfamethoxazole. (1973) (35)
Epidemiologic factors affecting antimicrobial resistance of common bacterial isolates (1987) (35)
Synergy and antagonism of combinations with quinolones (1991) (35)
Post-antibiotic suppressive effect of ciprofloxacin against gram-positive and gram-negative bacteria. (1987) (35)
Current practices in antimicrobial dosing. (1981) (35)
In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746 (1988) (35)
Cefatrizine Activity Compared with That of Other Cephalosporins (1979) (35)
Emerging trends in antimicrobial resistance in surgical infections. A review. (1994) (34)
Comparative In Vitro Activity and Clinical Pharmacology of Ticarcillin and Carbenicillin (1975) (34)
Gemfibrozil enhances the listeriacidal effects of fluoroquinolone antibiotics in J774 macrophages (1992) (34)
The 5′-Nucleotidases and Cyclic Phosphodiesterases (3′-Nucleotidases) of the Enterobacteriaceae (1968) (34)
In vitro and in vivo antibacterial activity of FR-31564, a phosphonic acid antimicrobial agent (1981) (34)
Achromobacter xylosoxidans bacteremia. (1987) (34)
Ciprofloxacin: an overview and prospective appraisal. (1987) (33)
Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis (1979) (33)
Use of piperacillin, a semisynthetic penicillin, in the therapy of acute exacerbations of pulmonary disease in patients with cystic fibrosis. (1980) (33)
Comparative in vitro activity of a new quinolone, AM-1091 (1989) (33)
Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis. (1988) (33)
Effect of Ethylenediaminetetraacetic Acid-Tris(hydroxymethyl)aminomethane on Release of the Acid-soluble Nucleotide Pool and on Breakdown of Ribosomal Ribonucleic Acid in Escherichia coli (1967) (32)
Carbenicillin and ticarcillin. (1982) (32)
The post-antimicrobial suppressive effect of quinolone agents. (1987) (32)
Intravascular clotting and acute pancreatitis in primary hyperparathyroidism. (1966) (32)
In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin (1993) (31)
The 5'-nucleotidases (uridine diphosphate sugar hydrolases) of the Enterobacteriaceae. (1968) (31)
Antibacterial Activity of Ceftriaxone (Ro 13-9904), a β-Lactamase-Stable Cephalosporin (1981) (31)
Effect of trimethoprim and trimethoprim-sulfamethoxazole on development of drug-resistant vaginal and fecal floras (1980) (31)
Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers (1981) (31)
Acute interstitial nephritis due to amoxicillin therapy. (1981) (31)
Activities of New Beta-Lactam Antibiotics Against Isolates of Pseudomonas aeruginosa from Patients with Cystic Fibrosis (1981) (31)
Use of cefotaxime, a beta-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms. (1981) (30)
Fosfomycin trometamol versus amoxycillin--single-dose multicenter study of urinary tract infections. (1990) (30)
Aspergillus endocarditis in children: case report and review of the literature. (1981) (30)
Imipenem: a new carbapenem antibiotic. (1988) (30)
Comparative antibacterial activity of a new oral cephalosporin, BMY-28100 (1987) (30)
Penicillin-binding proteins and role of amdinocillin in causing bacterial cell death. (1983) (29)
Factors influencing the in vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620 (1986) (29)
Postsplenectomy infection. (1981) (29)
Comparative pharmacokinetics of cefoperazone and cefamandole (1981) (29)
Infections due to gram-negative bacteria: an overview. (1985) (29)
Ceftizoxime: A Beta‐Lactamase‐Stable, Broad‐Spectrum Cephalosporin (1984) (28)
Kinetics of mezlocillin and carbenicillin (1978) (28)
Resistance of Xanthomonas maltophilia to antibiotics and the effect of beta-lactamase inhibitors. (1989) (28)
Purification and characterization of penicillinases from Salmonella typhimurium and Escherichia coli. (1970) (28)
Pharmacology of ceftizoxime compared with that of cefamandole (1981) (28)
Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks (1985) (28)
Overview of mechanisms of bacterial resistance. (1989) (28)
Aztreonam activity, pharmacology, and clinical uses. (1990) (28)
In vitro activity of Ro 23-9424, a dual-action cephalosporin, compared with activities of other antibiotics (1990) (27)
Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. (1993) (27)
Pharmacology of ticarcillin combined with clavulanic acid in humans. (1985) (27)
Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis. (1985) (27)
In vitro activity of E-1040, a novel cephalosporin with potent activity against Pseudomonas aeruginosa (1988) (27)
Laboratory assessment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins. (1995) (27)
In-vitro activity and β-lactamase stability of LY163892 (1988) (26)
Pathophysiologic basis for the use of third-generation cephalosporins. (1990) (26)
Chemical evolution of the fluoroquinolone antimicrobial agents. (1989) (26)
CLINICAL USES OF CEPHALOSPORINS (1982) (25)
In Vitro Activity and β-Lactamase Stability of Cefazaflur Compared with Those of β-Lactamase-Stable Cephalosporins (1979) (25)
The cyclic phosphodiesterases (3'-nucleotidases) of the enterobacteriaceae. (1968) (25)
Oral ciprofloxacin therapy of infection caused by multiply resistant bacteria other than Pseudomonas aeruginosa. (1986) (25)
Incidence of diarrhea and colitis associated with clindamycin therapy. (1977) (25)
Microbiologic aspects of fluoroquinolones. (1991) (25)
Controversies, dilemmas, and dialogues. Recommendations for antibiotic prophylaxis before endoscopy. (1989) (25)
New macrolide antibiotics: azithromycin and clarithromycin. (1992) (24)
The prospects of treatment failure in the chemotherapy of infectious diseases in the 1990s. (1995) (24)
Emergence of resistance to chloramphenicol in salmonella. (1977) (24)
Effect of 3-Lactamase Location inEscherichia coli on Penicillin Synergy (1969) (24)
Semisynthetic penicillin 6-(D(--)-alpha-carboxy-3-thienylacetamido) penicillanic acid active against Pseudomonas in vitro. (1971) (24)
CYTOLOGICALLY PROVEN SERONEGATIVE LYME CHOROIDITIS AND VITRITIS (1994) (24)
Pharmacological studies of 6 (D(-) -amino-p-hydroxyphenylacetamido) penicillanic acid in humans. (1970) (24)
Rapid, reproducible enzyme immunoassay for gentamicin (1980) (24)
Mechanisms of bacterial resistance to antimicrobial agents, with particular reference to cefotaxime and other beta-lactam compounds. (1982) (24)
A Review and Summary of the Pharmacokinetics of Cefoperazone: A New, Extended‐Spectrum β‐Lactam Antibiotic (1981) (24)
Toxoplasmosis, lymphoma, or both? (1969) (24)
New macrolides, azalides, and streptogramins in clinical practice. (1995) (23)
In Vitro Activity and Beta-Lactamase Stability of BL-S786 Compared with Those of Other Cephalosporins (1978) (23)
Tigemonam, an oral monobactam (1988) (23)
Tobramycin and ticarcillin therapy for exacerbations of pulmonary disease in patients with cystic fibrosis. (1976) (23)
In vitro activity and beta-lactamase stability of a monobactam, SQ 26,917, compared with those of aztreonam and other agents (1983) (23)
Synergistic activity of cefoperazone in combination with β-lactamase inhibitors (1981) (23)
Isolation of protoplasts in a case of enterococcal endocarditis. (1968) (23)
Experience with amoxicillin: an overall summary of clinical trials in the United States. (1974) (22)
In vitro activity and beta-lactamase stability of cefodizime, an aminothiazolyl iminomethoxy cephalosporin (1983) (22)
The role of inducible beta-lactamases in the antagonism seen with certain cephalosporin combinations. (1981) (22)
In vitro activity of dirithromycin (LY 237216) compared with activities of other macrolide antibiotics (1990) (22)
In vitro activity and beta-lactamase stability of a new penem, CGP 31608 (1987) (22)
Agar disk diffusion susceptibility characteristics of azlocillin, carbenicillin, mezlocillin, piperacillin, and ticarcillin (1979) (22)
Synergy of imipenem--a novel carbapenem, and rifampin and ciprofloxacin against Pseudomonas aeruginosa, Serratia marcescens and Enterobacter species. (1987) (21)
In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105 (1988) (21)
Clinical evaluation of piperacillin therapy for infection. (1981) (21)
In vitro activity and beta-lactamase stability of GR69153, a new long-acting cephalosporin (1991) (21)
Chloramphenicol and tetracyclines. (1987) (20)
Mezlocillin in the therapy of serious infections. (1979) (20)
Toxoplasmosis transmitted at autopsy. (1967) (20)
The pharmacokinetics of new cephalosporins: significance in clinical practice. (1984) (20)
The use of ceftizoxime in the treatment of critically ill patients infected with multiply antibiotic resistant bacteria. (1982) (19)
Synergy of fosmidomycin (FR-31564) and other antimicrobial agents (1982) (19)
In vitro activity and beta-lactamase stability of LJC 10,627 (1992) (19)
In Vitro Antibacterial Activity and β-Lactamase Stability of SCE-129, a New Cephalosporin (1979) (19)
Clinical evaluation of netilmicin therapy in serious infections. (1979) (19)
In vitro activity of LY146032 (Daptomycin), a new peptolide (1987) (19)
In-vitro activity of ceftazidime, a β -lactamase stable cephalosporin (1981) (19)
Optimal characteristics of agents to treat uncomplicated urinary tract infections (1992) (19)
Comparative studies of cefoxitin and cephalothin: an overview. (1979) (19)
Synergy of fosfomycin with beta-lactam antibiotics against staphylococci and aerobic gram-negative bacilli. (1986) (19)
Candida parapsilosis endocarditis: medical and surgical cure. (1979) (19)
The role of β-lactamase inhibitors in chemotherapy (1985) (18)
In vitro studies of a semisynthetic penicillin, 6-(D(-)- -carboxy-3-thienylacetamido) penicillanic acid (BRL 2288), active against Pseudomonas. (1970) (18)
Antimicrobial activity, bacterial resistance, and antimicrobial pharmacology. Is it possible to use new agents cost-effectively? (1985) (18)
Antibiotic resistance. Epidemiology and therapeutics. (1992) (18)
The use of mupirocin in controlling methicillin-resistant Staphylococcus aureus. (1990) (18)
The nephrotoxicity of antimicrobial agents (third of three parts). (1977) (18)
Combination of mezlocillin and azlocillin with cephalosporin antibiotics: cefoxitin, cefoperazone, cefotaxime and moxalactam. (1982) (18)
Antibiotic resistance of Salmonella in the eastern United States. (1969) (18)
Antimicrobial Resistance of Shigella Isolated in New York City in 1973 (1975) (17)
What should the clinician expect from the microbiology laboratory? (1978) (17)
Synergistic activity of mecillinam in combination with the beta-lactamase inhibitors clavulanic acid and sulbactam (1982) (17)
In vitro activity and beta-lactamase stability of cefmenoxime (1982) (17)
The pharmacokinetics of bacampicillin. (1981) (17)
Amdinocillin: A Novel Penicillin; Antibacterial Activity, Pharmacology and Clinical Use (1985) (17)
Relation of β-Lactamase Activity and Cellular Location to Resistance of Enterobacter to Penicillins and Cephalosporins (1972) (17)
Cefoxitin: an overview of clinical studies in the United States. (1979) (17)
Otitis media: antibiotic resistance of causative pathogens and treatment alternatives (1995) (17)
An update on fluoroquinolones (1992) (17)
In vitro activity of apalcillin compared with that of other new penicillins and anti-Pseudomonas cephalosporins (1982) (16)
Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection (1986) (16)
Meningitis, pneumonitis, and arthritis caused by Neisseria meningitidis group Y. (1975) (16)
Antibacterial activity of an oral penem, Sch 29482. (1982) (16)
Pharmacokinetics of Cefamandole in the Presence of Renal Failure and in Patients Undergoing Hemodialysis (1976) (16)
In vitro activity and beta-lactamase stability of a new difluoro oxacephem, 6315-S (1986) (16)
The role of amine buffers in EDTA toxicity and their effect on osmotic shock. (1969) (16)
Resistance of Escherichia coli and Salmonella typhimurium to carbenicillin. (1969) (16)
Stevens-Johnson syndrome due to Mycoplasma pneumoniae in an adult. (1985) (16)
In vitro activity of a new cephalosporin ME-1206 compared with other agents. (1991) (16)
Trimethoprim alone for treatment of urinary tract infection. (1982) (16)
Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia. (1989) (16)
Combination of ceftizoxime with azlocillin, mezlocillin, piperacillin and ticarcillin. (1982) (16)
Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection. (1984) (16)
Resistance of Pseudomonas aeruginosa to Imipenem (1992) (16)
New oral and parenteral quinolones. A summary. (1989) (16)
Aztreonam: the first monobactam. (1988) (16)
Studies on the mechanism of hypersensitivity phenomena. IV. An isometric smooth muscle assay system. (1961) (15)
Chronic granulomatous disease of childhood with renal involvement. (1974) (15)
beta-Lactamase inhibitory activity of iodopenicillanate and bromopenicillanate (1983) (15)
Thrombocytosis: an acute-phase reactant, not an adverse reaction to the new beta-lactam antibiotics. (1984) (15)
The safety and tolerance of mezlocillin. (1982) (15)
Synergistic activity of piperacillin in combination with beta-lactamase inhibitors (1980) (15)
Cephalosporins — Cefotaxime 10 years later, a major drug with continued use (1991) (15)
Major advances in antibacterial quinolone therapy. (1994) (15)
1-N HAPA gentamicin B, a new aminoglycoside active against gentamicin resistant isolates--activity compared to other aminoglycosides. (1978) (15)
The place of cephalosporins in antibacterial treatment of infectious diseases. (1980) (15)
The release of the acid-soluble nucleotide pool of E. coli by EDTA-Tris☆ (1966) (14)
Cost Effective Blood Cultures—Is It Possible or Impossible to Modify Behavior? (1986) (14)
The neurological aspects of Nocardia asteroides infection. (1968) (14)
Quinolones in perspective. (1990) (14)
Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin. (1987) (14)
Factors that affect the in-vitro activity of cephalosporin antibiotics. (1982) (14)
Activity of cephalosporins against coagulase-negative staphylococci. (1990) (14)
Effect of human lysozyme on gram-positive and gram-negative bacteria. (1968) (14)
Clinical utility of DNA gyrase inhibitors. (1989) (14)
Bacteraemia--a New York perception. (1990) (13)
Lack of Synergy of EDTA with Antimicrobials in Resistant Enterobacteriaceae (1970) (13)
Acute interstitial nephritis associated with carbenicillin therapy. (1978) (13)
General concepts on the chemotherapy of infectious diseases. (1987) (13)
Clinical perspectives on imipenem. (1983) (13)
Beta-lactamase inhibition: Therapeutic advances (1985) (13)
In vitro activity of A-16686, a new glycopeptide. (1986) (13)
Cephalosporins in the Treatment of Meningitis (2012) (13)
Intravenous/oral ciprofloxacin therapy of infections caused by multiresistant bacteria. (1989) (13)
A perspective on therapy of Lyme infection. (1988) (13)
Probenecid-resistant J774 cell expression of enhanced organic anion transport by a mechanism distinct from multidrug resistance. (1993) (12)
Endocarditis due to Kurthia bessonii. (1979) (12)
Structure-activity relationships: biological (1992) (12)
Antibacterial Activity and ,-Lactamase Stability of Temocillin (12)
Infection problems for the 1990's--do we have an answer? (1993) (12)
Do we need the third-generation cephalosporins? (1984) (12)
The comparative synergistic activity of amikacin, gentamicin, netilmicin and azlocillin, mezlocillin, carbenicillin and ticarcillin against Serratia marcescens. (1978) (12)
Comparison and Evaluation of Ticarcillin and Carbenicillin Using Disk Diffusion Methods (1976) (12)
Activity of cefsulodin and other agents against Pseudomonas aeruginosa. (1984) (12)
Prophylaxis--has it at last come of age? (1979) (12)
The antibacterial activity of thienamycin against multiresistant bacteria-comparison with beta-lactamase stable compounds. (1980) (12)
The pharmacology of orally administered ciprofloxacin. (1985) (11)
Pharmacokinetics of Intravenous Cefotaxime in Patients Undergoing Chronic Hemodialysis (1981) (11)
Antibacterial activity of amifloxacin (WIN 49, 375), a new quinolone agent. (1985) (11)
Relation of Lipopolysaccharide and Fatty Acid Ester Release to the Ethylenediaminetetraacetic Acid Alteration of Permeability in Enterobacteriaceae (1970) (11)
HR 756, aNewCephalosporin Active Against Gram-Positive andGram-Negative Aerobic andAnaerobic Bacteria (1979) (11)
Diffusion Disk Susceptibility Testing with Cefotaxime (1979) (11)
In vitro activity of fleroxacin in combination with other antimicrobial agents. (1993) (11)
In-vitro activity of two new quinolone antimicrobial agents, S-25930 and S-25932 compared with that of other agents. (1987) (11)
NEPHROTOXICITY OF ANTIMICROBIAL AGENTS — THE FIRST OF THREE PARTS (1977) (11)
β-Lactamase stability of cefoxitin in comparison with other β-lactam compounds (1983) (11)
Resistance of Pseudomonas aeruginosa to imipenem. (1992) (10)
Activity of 5-Episisomicin Compared with That of Other Aminoglycosides (1978) (10)
Current state of infectious diseases--potential areas of directed therapy with aztreonam. (1985) (10)
In-vitro activity of ceftazidime, a beta-lactamase stable cephalosporin. (1981) (10)
Relation of Cell Wall Lipid Content of Serratia marcescens to Resistance to Antimicrobial Agents (1974) (10)
Ceftibuten: minimal inhibitory concentrations, postantibiotic effect and beta‐lactamase stability—a rationale for dosing programs (1995) (10)
Molecular modifications of antimicrobial agents to overcome drug resistance. (1976) (10)
Antibiotic resistance of salmonella in northeastern United States 1968-199. (1971) (10)
In vitro activity of ME1228, a new parenteral cephalosporin (1989) (10)
Effect of beta-lactamase location in Escherichia coli on penicillin synergy. (1969) (10)
Quinolones as Broad-spectrum Agents (1990) (9)
Synergy and Antagonism of Fluoroquinolones with Other Classes of Antimicrobial Agents (2012) (9)
Antibacteroides and β-lactamase inhibitory activities of moxalactam (1981) (9)
Management and prevention of infectious diseases (1985) (9)
Postantibiotic effect of ceftibuten on respiratory pathogens (1995) (9)
In-vitro activity and beta-lactamase stability and inhibitory properties of a new penem antibiotic, Sch 34343. (1985) (9)
The effect of exchange transfusion on the blood levels of ampicillin and gentamicin in neonates (2005) (9)
In vitro antimicrobial activity of 6(D(-) -amino-p-hydroxyphenylacetamido) penicillanic acid, a new semisynthetic penicillin. (1970) (9)
Pharmacokinetics of moxalactam in patients with renal failure and during hemodialysis (1981) (9)
Synergy of azlocillin with aminoglycosides. (1983) (9)
In vitro evaluation of cephacetrile, a new cephalosporin antibiotic. (1972) (9)
The use of cefepime (BMY 28142) to treat respiratory infections. (1989) (9)
Comparative Inhibition of,B-Lactamases byNovelf8-Lactam Compounds (1979) (9)
β-Lactamases, β-lactamase inhibitors, and skin and skin-structure infections (1990) (9)
Aminopenicillins - clinical pharmacology and use in disease states. (1975) (9)
Systemic infections treated with amdinocillin in combination with other beta-lactam antibiotics. (1983) (9)
New penicillins and their use in pediatrics. (1983) (8)
Summary of imipenem/cilastatin symposium (1985) (8)
Cephalosporin antibiotics: molecules that respond to different needs. (1988) (8)
Antimicrobial Chemotherapy, 1934–1994 (1994) (8)
New trends in urinary tract infections : the single-dose therapy (1988) (8)
In vitro activity and beta-lactamase stability of U-63196E, a novel cephalosporin (1983) (8)
In vitro antimicrobial activity of the new antibiotic vermisporin (1992) (8)
Antibacterial Activity of Ceftizoxime, a ,B-Lactamase-Stable Cephalosporin (8)
A symposium on the tetracyclines: a major appraisal. Introduction. (1978) (8)
Glycopeptides and lipopeptides Agents trying to meet the demands of the future (1988) (8)
Cefoxitin: microbiology, pharmacology and clinical use. (1978) (8)
Hemorrhagic bullae associated with salmonella septicemia. (1981) (8)
Antimicrobial agents--mechanisms of action and clinical usage. (1973) (8)
Pharmacokinetics, microbiology, cost: interrelated problems for the 1990s that impact on the use of fluoroquinolone antimicrobial agents. (1992) (8)
The Enchanted Ring: The Untold Story of Penicillin (1982) (8)
How is the medical student being trained in microbiology and infections? (1978) (8)
Ticarcillin plus clavulanic acid in the treatment of pneumonia and other serious infections. (1985) (8)
Antistaphylococcal penicillins. (1982) (8)
Cefotaxime and desacetylcefotaxime: an example of advantageous antimicrobial metabolism. (1984) (8)
Penicillin-binding proteins and beta-lactamases: their effects on the use of cephalosporins and other new beta-lactams. (1987) (8)
Bacampicillin Hydrochloride: Chemistry, Pharmacology, and Clinical Use (1982) (8)
Antibacterial therapy: problems and promises, Part II. (1990) (7)
Rapid, reproducible enzyme immunoassay for tobramycin (1981) (7)
Correlation of Netilmicin Disk Diffusion Susceptibility and Agar Dilution Susceptibility (1979) (7)
Quinolones: A New Class of Antimicrobial Agents With Wide Potential Uses (1988) (7)
In vitro activity and beta-lactamase stability of a new monobactam, B0-1165 (1987) (7)
Lepromatous leprosy masquerading as disseminated tuberculosis. (1979) (7)
In vitro activity of midecamycin, a new macrolide antibiotic (1983) (7)
In vitro activity of SCE-2787, a new cephalosporin with potent activity against Pseudomonas aeruginosa and members of the family Enterobacteriaceae (1994) (7)
Antibiotic resistance of fecal Escherichia coli. A comparison of samples from children of low and high socioeconomic groups. (1973) (7)
The activity of metal compounds against aerobic and anaerobic bacteria. (1992) (7)
In vitro activity of pefloxacin compared to that of quinolones and other antimicrobial agents. (1984) (7)
Therapeutic and epidemiologic recommendations to reduce the spread of type-I beta-lactamase resistance. (1992) (7)
Effect of β-Lactamase Location in Escherichia coli on Penicillin Synergy (1969) (7)
Beta-Lactamase Activity in Shigella sonnei (1976) (7)
Antibacterial activity of DL 473, a C3-substituted rifamycin derivative (1983) (7)
FOSFOMYCIN TROMETAMOL : MANAGEMENT OF LOWER URINARY TRACT INFECTIONS (1990) (7)
A perspective on the present contribution of beta-lactamases to bacterial resistance with particular reference to induction of beta-lactamase and its clinical significance. (1985) (7)
Disk susceptibility of ofloxacin, a new carboxyquinolone (1985) (7)
New strategies for the 1990's: antibacterial therapy. (1991) (7)
Cefoxitin sodium and cephalothin in the treatment of serious infections. (1978) (7)
Quinolones revisited: where are we? (1987) (7)
Lomefloxacin: development of a once-a-day quinolone. Proceedings of a symposium. April 23-25, 1990, Miami, Florida. (1992) (6)
Emergence and mechanisms of bacterial resistance in surgical infections. (1995) (6)
Antibiotics in the second half of the 1980s. Areas of future development and the effect of new agents on aminoglycoside use. (1986) (6)
7 – The Quinolones: Prospects (1988) (6)
Adult Hemophilus influenzae meningitis; associated with disseminated intravascular coagulation. (1969) (6)
Oral ofloxacin therapy of infections due to multiply-resistant bacteria. (1991) (6)
ORAL β-LACTAM ANTIBIOTICS FROM 1960 TO 1993 (1993) (6)
Aminopenicillins - clinical pharmacology and use in disease states. (1975) (6)
Ciprofloxacin: major advances in intravenous and oral quinolone therapy: an introduction (1989) (6)
Interbacterial Transfer of R Factor in Humans (1973) (6)
Fleroxacin combined with rifampin. (1991) (6)
Antimicrobial activity and beta-lactamase stability of foramidocillin (1986) (6)
The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin. (1986) (6)
Unusual nosocomial infections (1984) (6)
Advances in cephalosporin therapy. (1985) (6)
Comparative in vitro activity of the new oral macrolide azithromycin (1988) (5)
1st International Ciprofloxacin Workshop, Leverkusen, 6-8 November 1985 : presidents, H.C. Neu, D. Adam, R. Krebs : proceedings (1986) (5)
Changing patterns of hospital infections: implications for therapy. Changing mechanisms of bacterial resistance. (1984) (5)
The efficacy of ceftizoxime in treating infections due to organisms resistant to other antibiotics. (1982) (5)
The role of beta-lactamase inhibitors in chemotherapy. (1985) (5)
In-vitro activity of WIN 57273 compared to the activity of the fluoroquinolones and two β-lactam antibiotics (1991) (5)
The pharmacology of clavulanic acid and ticarcillin combined. (1984) (5)
Beta-lactamase inhibition by acetylmethylene penicillanic acid compared to that of clavulanate and sulbactam. (1988) (5)
Introduction: The patient at risk for infection (1984) (5)
Antimicrobial agents: the old and the new. (1989) (5)
Clinical Pharmacokinetics in Preventive Antimicrobial Therapy (1977) (5)
Transfusion-induced malaria after open-heart surgery. (1975) (5)
Antibacterial activity of a monocyclic beta-lactam SQ 26,776. (1981) (5)
Tazobactam prevention of emergence of resistance. (1989) (5)
Studies on the mechanism of hypersensitivity phenomena. V. Antigen-antibody interaction in the guinea-pig small intestine. (1961) (5)
Penicillins--new insights into their mechanisms of activity and clinical use. (1982) (5)
Post-antibiotic effect of the new streptogramin RP 59500 (1992) (5)
Contemporary antibiotic therapy in otolaryngology. (1984) (5)
In Vitro Activity and ,-Lactamase Stability of a New Monobactam, BO-1165 (4)
Antibacterial activity of rokitamycin compared with that of other macrolides. (1991) (4)
Antibacteroides and beta-lactamase inhibitory activities of moxalactam. (1981) (4)
In vitro studies of cephanone, a 3-heterocyclic-thiomethyl cephalosporin derivative. (1973) (4)
In vitro activity of dactimicin, a novel pseudodisaccharide aminoglycoside, compared with activities of other aminoglycosides (1989) (4)
In vitro activity of temafloxacin, a new difluoro quinolone antimicrobial agent (1988) (4)
What do β-lactamases mean for clinical efficacy? (2005) (4)
The patient at risk for infection: A summary (1984) (4)
NEUROTOXICITY OF TICARCILLIN (1979) (4)
Use of antimicrobial agents to treat central nervous system infection. (1992) (4)
In vitro antibacterial activity and beta-lactamase stability of E-0702, a new cephalosporin (1983) (4)
In vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620 compared to that of other antimicrobial agents. (1987) (4)
The place of quinolones in bacterial infections. (1991) (4)
Combination of ofloxacin and other antimicrobial agents. (1990) (4)
In vitro activity of LY264826 compared to other glycopeptides and daptomycin. (1991) (4)
Synergistic Activity of Piperacillin in Combination with fl-Lactamase Inhibitors (4)
Relation of beta-lactamase activity and cellular location to resistance of Enterobacter to penicillins and cephalosporins. (1972) (4)
PROGRESS AND PERSPECTIVES ON BETA‐LACTAMASE INHIBITION: A REVIEW OF AUGMENTIN (1985) (4)
The efficacy of mezlocillin in the therapy of bacteraemia. (1982) (4)
Quinolones : the present and the future (1994) (4)
Parasitic infections: therapeutic considerations. (1988) (4)
Clinical Pharmacology of the Antimicrobial Agents for Infections in the Ear, Nose and Throat (1981) (4)
In Vitro Activity and ,-Lactamase Stability of U-63196E, a Novel Cephalosporin (4)
The in-vitro activity of EN 272, a quinolone-7-carboxylic acid, in comparison with other quinolones. (1985) (4)
In-vitro activity and beta-lactamase stability of LY163892. (1988) (4)
The biochemical basis of antimicrobial and bacterial resistance. (1987) (4)
Synergy of sulbactam and ampicillin against methicillin-resistant staphylococci. (1986) (4)
The AIDS Knowledge Base: A Textbook on HIV Disease From the University of California, San Francisco, and the San Francisco General Hospital (1990) (4)
Considerations about the relationship of inhibitory concentrations and the pharmacologic and toxic properties of antimicrobial agents. (1983) (4)
Diagnosis and treatment: drugs five years later. Amoxicillin. (1979) (4)
Ceftriaxone in the treatment of serious infections, particularly after surgery. (1984) (4)
In vitro activity and susceptibility to hydrolysis of S-1006 (1992) (3)
Fluid management in haemophilus influenzae meningitis (2005) (3)
-lactamase production by Pseudomonas aeruginosa. (1970) (3)
Treatment of serious infections with intravenous ciprofloxacin. (1987) (3)
Antibacterial therapy: problems and promises, Part I. (1990) (3)
THE PHARMACOLOGY OF NEWER AMINOGLYCOSIDES, WITH A CONSIDERATION OF THE APPLICATION TO CLINICAL SITUATIONS (1977) (3)
The use of azlocillin to treat serious infections. (1983) (3)
Semisynthetic Penicillin 6-[d(—)-α-Carboxy-3-Thienylacetamido] Penicillanic Acid Active Against Pseudomonas In Vitro (1971) (3)
Beta-lactamase stability of cefoxitin in comparison with other beta-lactam compounds. (1983) (3)
Sisomicin therapy of serious gram-negative infections (1976) (3)
Pyridinium 2-azo-p-dimethylaniline chromophore, a chromogenic reagent for beta-lactamase testing compared to nitrocefin (1984) (3)
The in vitro activity and beta-lactamase stability of cefpirome (HR 810), a pyridine cephalosporin agent active against staphylococci, enterobacteriaceae and pseudomonas aeruginosa (1985) (3)
Antibacterial Activity and ,-Lactamase Stability of Ceftazidime , an Aminothiazolyl Cephalosporin Potentially Active Against Pseudomonas aeruginosa (3)
Comparative antibacterial activity of an arylglycyl oral cephalosporin, LY164846 (1986) (3)
Pharmacokinetics of amdinocillin and pivamdinocillin in normal volunteers. (1983) (3)
Urinary tract infections: 1982--use of new concepts to guide therapy. (1983) (3)
Pharmacokinetics of sisomicin in normal patients and those with depressed renal function (1976) (3)
The in-vitro activity of O-demethylfortimicin. (1983) (3)
In Vitro Activity of Chloramphenicol and Thiamphenicol Analogs (3)
Beta-lactamases, beta-lactamase inhibitors, and skin and skin-structure infections. (1990) (3)
Trends in the development of beta-lactam antibiotics. (1984) (3)
Synergistic activity of cefoperazone in combination with beta-lactamase inhibitors. (1981) (3)
Clinical Therapeutic Conference (1992) (3)
An international review of amdinocillin: a new beta-lactam antibiotic. (1983) (3)
Paul Ehrlich: Scientist for Life (1985) (3)
In vitro activity of HRE 664, a penem antibiotic. (1990) (3)
The in-vitro activity and beta-lactamase stability of carumonam. (1986) (3)
Azlocillin andMezlocillin: NewUreido Penicillins (1978) (3)
What do beta-lactamases mean for clinical efficacy? (1983) (3)
Bacteremia in the 1980s with special reference to the role of cefotaxime. (1981) (2)
In vitro activity of CP-74,667. A new fluoroquinolone compared with other quinolones. (1992) (2)
Pharmacokinetics ofCefamandole inthePresence ofRenal Failure andinPatients Undergoing Hemodialysis (1976) (2)
Quinolones. An overview. (1990) (2)
Issues in gram-positive infections: the present and the future. (1988) (2)
Treatment of penicillin-resistant infections. (1986) (2)
In vitro activity of the new glycopeptide decaplanin (1992) (2)
Good antimicrobial prescribing. Clinical uses of cephalosporins. (1982) (2)
Introduction: Aztreonam: Continued efficacy and safety (1990) (2)
In vitro activity of MC-352, a new 16-membered macrolide (1992) (2)
Rapid, Reproducible EnzymeImmunoassay forGentamicin (1980) (2)
Microbiology of bacterial meningitis pathogens. (1992) (2)
Antimicrobial effects of the combination of ceftibuten and an orally absorbed penem SCH 29482. (1991) (2)
Emerging perspectives in management and prevention of infectious diseases. A summary. (1985) (2)
Comparative InVitro Activity andP-Lactamase Stability ofFK482, aNewOralCephalosporin (1989) (2)
Comparative in vitro activity of a new fluorinated 4-quinolone, QA-241. (1989) (2)
Summary Lomefloxacin: Development of a once-a-day quinolone (1992) (2)
Controversies in the Diagnosis and Management of Infectious Diseases: Introduction to the Series (1986) (2)
Pharmacokinetics ofIntravenous Piperacillin inPatients Undergoing Chronic Hemodialysis (1979) (2)
Acute pulmonary edema in the dog (1987) (2)
The role of cellular and humoral factors in infections. (1976) (2)
The epidemiology of hepatitis B infection in housestaff (2005) (2)
Macrolides: Problems and Promises (1988) (2)
A decade of progress in cephalosporin use: Summary (1990) (2)
Optimal antibiotic therapy in bronchopulmonary infections (2005) (2)
The use of drugs in renal failure. (1979) (1)
Antimicrobial Resistance and R-Factors in Salmonella Isolated from Humans and Animals (1975) (1)
Infection control: progress and problems. Introduction. (1975) (1)
Role of mycoplasma in exudative pharyngitis. (1969) (1)
Relation of1-Lactamase Activity andCellular Location toResistance ofEnterobacter toPenicillins andCephalosporins (1972) (1)
Just how good is amoxicillin? (1975) (1)
Use of fluoroquinolone antimicrobial agents by cardiovascular and cardiopulmonary surgeons. (1990) (1)
Diagnosis and treatment of five opportunistic infections. (1972) (1)
Relation of 1-Lactamase Activity and Cellular Location to Resistance of Enterobacter to Penicillins and Cephalosporins (1)
Inactivation of ,B-Lactam Antibiotics by Legionella pneumophila (2003) (1)
In osteomyelitis the initial treatment is crucial. (1980) (1)
Guidelines to antibiotic therapy in renal failure. (1973) (1)
Editors' roundtable: Current formulas for P & T Committee success (Part 1). (1987) (1)
In-vitro activity of FCE 22101 and synergy studies with other antimicrobial agents. (1989) (1)
Endocarditis: The problems remain and multiply (2005) (1)
Pharmacokinetic Studies of Serum Levels and Urinary Excretion of Ticarcillin after Intravenous and Intramuscular Administration to Patients with Normal and Abnormal Renal Function (1976) (1)
Treatment of methicillin-resistant Staphyloccus infections (1984) (1)
In vitro activity of YTR-830H in combination with beta-lactamase unstable beta-lactams. (1989) (1)
Parenteral amoxicillin in the treatment of infections in hospitalized patients. (1980) (1)
Use of Personal Items Could Present Problems (1985) (1)
The in vitro activity and β-lactamase stability of cefpiramide compared with other β-lactam antibiotics (1985) (1)
Infections caused by gram-negative pathogens: new clinical considerations. (1975) (1)
Aztreonam: A novel monocyclic beta-lactam antibiotic (1985) (1)
The in vitro activity and beta-lactamase stability of cefpiramide compared with other beta-lactam antibiotics. (1985) (1)
Antibacterial activity and beta-lactamase stability of MDL 19,592, an oral cephalosporin. (1989) (1)
Blind therapy in emergencies. (1975) (1)
Serratia marcescens sternal wound infections after cardiac surgery: A 1986 update (1987) (1)
Use of Aztreonam in the Treatment of Serious Infections Due to Multiresistant Gram-Negative Organisms, Including Pseudomonas Aeruginosa (1985) (1)
Antimicrobial agents: bacterial/fungal (1989) (1)
Infective endocarditis. (1975) (1)
Colonization resistance: Fact or facy, significant or insignificant? (1988) (1)
In vitro activity of cefcanel versus other oral cephalosporins (1991) (1)
In vitro activity of an oxycephem OCP 9-176 compared with its sulfur analog and other beta-lactams. (1991) (1)
Infectious diseases and antimicrobial agents (1981) (1)
InVitro Activity ofS-Ofloxacin (1989) (1)
Summary of the symposium on amoxicillin. (1974) (1)
InVitro Activity andP-Lactamase Stability ofaMonobactam, SQ26,917, Compared withThoseofAztreonam andOther Agents (1983) (1)
Considerations for selection of oral antibiotics in a new era of health care (1995) (1)
The comparative in vitro activity and beta-lactamase stability of a new ureido penicillin. (1979) (1)
Editors' roundtable: current formulas for P & T Committee success. (Part 2). (1987) (1)
Tentative Ideal Profile of a Drug in Single-Dose Therapy of Urinary Tract Infections (1988) (1)
Therapy of serious infections with cefamandole (2005) (1)
Coming in postgraduate medicine. (1975) (1)
The use of moxalactam in the treatment of serious infections due tu multi-resistant organisms (1983) (1)
Current status of cefotaxime sodium: a new cephalosporin. Symposium held at Phoenix, USA, 12-13 January 1981. (1982) (1)
Organic Anion Transporters Promote the Secretion of Anionic Antibiotics from Cells of the J774 Macrophage-Like Cell Line (1993) (1)
Comparative in vitro activity of the new fluoroquinolone BMY-40062 (1990) (1)
The effect of the combination of erythromycin with new beta-lactam antibiotics against gram-negative aerobic respiratory pathogens. (1986) (0)
The Inhibitory Quotient-Reply (1982) (0)
Trends in treating geriatric infections at home. (1988) (0)
Antimicrobial agents in patients with renal disease. (1977) (0)
The 10 Most Commonly Asked Questions About Cephalosporins (1994) (0)
Virus and Rickettsial Diseases of Man, ed 4. (1968) (0)
In vitro activity of Ro 09-1428 compared to other cephalosporins (1991) (0)
Newer antibiotics. (1973) (0)
Optimal Use of Antimicrobial Agents (1989) (0)
The microbiology laboratory and the physician. (1979) (0)
Viruses of Vertebrates. (1973) (0)
Carbenicillin and Ticarcillin (1982) (0)
InVitroStudyofNetilmicin Compared withOther Aminoglycosides (1976) (0)
Mezlocillin—a broad specturm penicillin An update (1983) (0)
Changing patterns of bacterial infections and antibiotic therapy : proceedings of a symposium held in Letterman General Hospital, San Francisco, Calif., 7-8 May 1970 (1971) (0)
Cefuroxime, aBeta-Lactamase-Resistant witha BroadSpectrum ofGram-Positive and-Negative Activity (1978) (0)
An introduction to controversies in the diagnosis and management of infectious diseases. (1987) (0)
The Use of Mupirocin in Controlling Methicillin-Resistant Staphylococcus aureus (1990) (0)
Fluoroquinolones—Where are we? (1990) (0)
InVitro Activity and 3-Lactamase Stability ofFK-037, aParenteral Cephalosporin (1993) (0)
Contents, Supplement 1, 1990 (2004) (0)
Progression of Group A Streptococcal Necrotizing Fasciitis During Moxalactam Therapy-Reply (1984) (0)
Average length of stay in patient's with aids (1991) (0)
Therapy of the internal diseases of domestic animals. (1986) (0)
The quinolone antibiotics (1989) (0)
β-Lactamase blocking agents : Proceedings of a workshop held at the 14th International Congress of Chemotherapy, Kyoto, 1985 (1986) (0)
Update: bacterial resistance to antimicrobial agents. (1970) (0)
Drug-resistant tuberculosis; serious problem. (1980) (0)
Introduction scope of the meeting (1990) (0)
Clavulanic Acid, aNovelInhibitor off3-Lactamases (1978) (0)
A Symposium on the Tetracyclines: A Major Appraisal: The New York Academy of Medicine: Symposium Summary (1978) (0)
Molecular modifications of antibiotics and antibiotic combinations to overcome bacterial resistance (1979) (0)
Nosocomial klebsiella sepsis following hemodialysis (1987) (0)
A new beta-lactam antibiotic: is it a major advance? (1979) (0)
An analysis of tobramycin prescribing practices (1989) (0)
Comparison of the Antibacterial Activity of Beta-Lactam Antibiotics and their Resistance to Hydrolysis by Beta-Lactamases (1975) (0)
A case of pasteurella multocida meningitis in an infant (1991) (0)
P&T Committee review of fluconazole: an effective alternative to antifungal therapy. (1990) (0)
Penicillin: Meeting the Challenge (1986) (0)
Comparative in vitro activity and beta-lactamase stability of CGP 31523A, a new aminothiazolyl cephalosporin. (1986) (0)
Infections in intensive care patients: use of new B-lactams. (1984) (0)
Current and Future Directions in the Use of Antimicrobial Agents: Sections on Medicine, Pediatrics, and Surgery the New York Academy of Medicine: Concluding Remarks (1984) (0)
A New Era of Antimicrobial Agents (1994) (0)
In vitro activity of PD 117596-2, a broad-spectrum difluoroquinolone (1989) (0)
In-vitro activity of WIN 57273 compared to the activity of other fluoroquinolones and two beta-lactam antibiotics. (1991) (0)
Quinolones: careful use will preserve their value. (1988) (0)
Antimicrobial activity and beta-lactamase stability of SK&F 88070 compared with other agents. (1986) (0)
[Clinical study on development of resistance of respiratory bacterial pathogens to ofloxacin and ciprofloxacin]. (1987) (0)
InVitro Activity and,B-Lactamase Stability ofCefmenoxime (1982) (0)
InVitro Activity ofMidecamycin, aNewMacrolide Antibiotic (1983) (0)
Synergy ofFosmidomycin (FR-31564) andOther Antimicrobial (1982) (0)
Fosfomycin trometamol single dose: significance and management of lower UTI's. (1990) (0)
InVitro Activity ofCI-934, a NewQuinolone, Compared withThat ofOtherQuinolones andOtherAntimicrobial Agents (1986) (0)
Virology Monographs, vol 3. (1969) (0)
Frontiers of infectious diseases: new antibacterial strategies. Proceedings of an international symposium sponsored by Glaxo Research, Brocket Hall, Hertfordshire 30 June-3 July 1990. (1990) (0)
The penicillins. II. Overview of pharmacology, toxicology, and clinical use. (1977) (0)
Focus on HIV (1993) (0)
Controversies in infectious diseases: an analysis. (1987) (0)
An investigation into the biochemical pathways of morphogenesis in the mouse (strain 129). (1956) (0)
Newer antimicrobial agents. (1975) (0)
Virology Monographs: Echoviruses and Reoviruses. (1969) (0)
The activity and beta-lactamase stability of cefotetan compared to other beta-lactam antibiotics. (1985) (0)
Ampicillin Resistance and Beta-Lactamase Activity in Clinical Isolates of Shigella Sonnei (1976) (0)
Definitions et classifications des β-lactamases (1988) (0)
The use of new antimicrobial agents in serious life-threatening infections--pros and cons. (1988) (0)
Lidocaine Water Water Lidocaine Water Water Lidocaine Water Water Lidocaine Water Water Lidocaine (0)
THE COMPARATIVE IN VITRO ACTIVITY AND /3-LACTAMASE STABILITY OF A NEW UREIDO PENICILLIN HAROLD (2006) (0)
Comparative clinical efficacy of cefetamet pivoxil in lower respiratory tracts infection. Discussion (1994) (0)
A review of the pharmacology of cefamandole. (1980) (0)
Subject Index, Vol. 27, 1981 (1981) (0)
The activity of cefbuperazone, a 7 alpha-methoxy 7 beta acyl ureido cephalosporin. (1985) (0)
Controversies in the diagnosis and management of infectious diseases: conclusions. (1987) (0)
New Trends in the Treatment of Urinary Tract Infections (1988) (0)
Clinical Role OF Pseudomonas Aeruginosa (2020) (0)
Shigella sonnei (0)
Aminoglycosides: Do We Need New Agents? (2012) (0)
Once‐Daily Oral Antimicrobial Therapy: Is a Consensus Possible? (1992) (0)
Azlocillin—An antipseudomonas pencillin (1983) (0)
Review of Medical Microbiology, ed 10. (1973) (0)
Treatment of gonococcal infections, revisited. (1979) (0)
InVitro Activity and1-Lactamase Stability ofa NewDifluoro Oxacephem, 6315-S (1986) (0)
Streptogramins—agents for the 1990s (1990) (0)
FIV(FTLV)-infection in cat: 11 cases - a contribution to the epidemiology, clinical symptoms and to the course of disease (1989) (0)
The penicillins. I. Overview of microbiology. (1977) (0)
General discussion session V on international guidelines (1992) (0)
Rectal colonization with vancomycin-resistant Enterococcus faecium/faecalis (VREF) in the cardiothoracic surgical patient (1994) (0)
Clinical results with a new antifungal agent. (1974) (0)
Carriage of methicillin-resistant S. aureus (MRSA) by hospital staff in a dermatology unit (1994) (0)
Summary of conference (1989) (0)
Therapy of serious gram-negative infections with a new aminoglycoside (1979) (0)
PHARMACOKINETICS OF CEFOTAXIME 593 (2003) (0)
A new antibiotic combination of unusually broad spectrum. (1973) (0)
Aspergillus Endocarditis in Childen: Case Report and Review of the Literature (1981) (0)
Book Review Infective Endocarditis Second edition. Edited by Donald Kaye. 497 pp., illustrated. New York, Raven Press, 1992. $85. 0-88167-892-9 (1993) (0)
Letters to the Editor (1982) (0)
Introduction (1988) (0)
Sterile view hoods — a new infection risk? (1993) (0)
Oedematous swelling of the limbs in puppies – a sign of primary (congenital) lymphoedema (2003) (0)
PENICILLINS - NEW INSIGHTS INTO THEIR MECHANISMS OF ACTIVITY AND CLINICAL USE (2006) (0)
Concluding Remarks (2012) (0)
THE BIOCHEMICAL BASIS OF ANTIMICROBIAL AND BACTERIAL RESISTANCE* (2006) (0)
Comparative in vitro activity and beta-lactamase stability of RU29246, the active metabolite of HR916B (1992) (0)
Associated with Clindamycin Therapy (1977) (0)
The changing ecology of bacterial infections in children. (1976) (0)
Distribution of FIV-(FTLV-) seropositive cats in West Germany - first results and interpretation (1989) (0)
Interbacterial Transfer ofR Factor inHumans (1973) (0)
InVitro Activity and1-Lactamase Stability ofLJC10,627 (1992) (0)
New Broad-Spectrum Penicillins (2012) (0)
Recent Developments in Oral Antibiotic Therapy: Bacampicillin Update: Section on Pediatrics and Section on Medicine the New York Academy of Medicine: Introductory Remarks (1983) (0)
Stability in the presence of widespread β-lactamases. A prerequisite of the antibacterial activity of β-lactam drugs. Discussion (1994) (0)
Urinary tract infections in the 1980s. (1983) (0)
Manual of Clinical Microbiology. (1970) (0)
Use of the newer agents for antibiotic-resistant infection: Harold C. Neu, MD. Interview by Richard L. Peck. (1985) (0)
Pharmacokinetic and clinical studies of cefixime: a worldwide review. (1989) (0)
Cephalosporins—Cefotaxime/desacetylacefotaxime revisited: A summary (1989) (0)
Problems with old diseases related to social and pharmaceutical industry situations. (1988) (0)
Commentary 1 (2012) (0)
THE PHARMACOKINETICS OF NEW CEPHALOSPORINS: SIGNIFICANCE IN CLINICAL PRACTICE* (2006) (0)
Discussion on : aztreonam's role in the treatment of gram-negative infections (1990) (0)
Beta-Lactamase Stability ofHR 756, aNovelCephalosporin, Compared toThatofCefuroxime andCefoxitin (1978) (0)
Peritonitis associated with automated peritoneal dialysis (APD) (1989) (0)
Comparative in vitro activity and clinical pharmacology of ticarciliin and carbenicillin. (1975) (0)
In vitro activity and beta-lactamase stability of the new oral cephalosporin Bay v 3522 (1990) (0)
Controversies in the Diagnosis and Management of Infectious Diseases. Session IV: Immunology. Summary and Discussion (1987) (0)
Clinical advances in oral antibiotic therapy. Summary and closing remarks. (1979) (0)
Infections in Cancer Patients: Monograph Series of the European Organization for Research on Treatment of Cancer (1983) (0)
INFECTIONS CAUSED BY GRAM-NEGATIVE PATHOGENS: NEW CLINICAL CONSIDERATIONS* (2006) (0)
False-positive tuberculosis cultures occurring midst a true increase in tuberculosis (1989) (0)
Outlook improves for meningitis: a rare nosocomial infection. (1983) (0)
Title Page / Contents / Opening Remarks (1988) (0)
Bacterial Endocarditis from 1938 to 1967 at the Presbyterian Hospital in New York City. (1969) (0)
A New β-Lactam Antibiotic: Is It a Major Advance? (1979) (0)
Effect of Ethylenediaminetetraacetic Acid-Tris(hy- droxymethyl)aminomethane (0)
CNS infection. First things first. (1985) (0)
Cefaclor: InVitro Spectrum ofActivity andBeta-Lactamase Stability (1978) (0)
Primary congenital lymphoedema in seven young Labrador dogs, a German Shepherd dog and a Canadian wolf. (Literatury view, clinical forms, diagnosis and therapy) (1994) (0)
Effect ofEthylenediaminetetraacetic Acid-Tris (hy- droxymethyl)aminomethane on Release ofthe Acid-soluble Nucleotide Poolandon Break- downofRibosomal Ribonucleic Acid inEscherichia coli (1967) (0)
Antibiotic prophylaxis in surgery : current concepts : a symposium (1981) (0)
Introduction to the Symposium (1985) (0)
In vitro activity and beta-lactamase stability of cefazaflur compared with those of beta-lactamase-stable cephalosporins. (1979) (0)
Symposium on Infectious Diseases: Section on Medicine, the New York Academy of Medicine: Introduction (1982) (0)
Infections and Antibiotic Usage in Patients with Renal Diseases (1983) (0)
Comparative Antibacterial Activity ofa New OralCephalosporin (1987) (0)
Relation ofCell WallLipid Content ofSerratia marcescens toResistance toAntimicrobial Agents (1974) (0)
Chronic beryllium lung disease. Disease in search of work history. (1967) (0)
A case of Bordetella pertussis in a pediatric house officer (1990) (0)
Aztreonam: an appraisal. (1986) (0)
Another cephalosporin! (1978) (0)
Antimicrobial activity and beta-lactamase stability of BMY-28232, parent compound of an oral cephalosporin (1990) (0)
Alexander Fleming: The Man and the Myth (1985) (0)
Introductory remarks. (2020) (0)
Activity of5-Episisomicin Compared withThatofOther Aminoglycosides (1978) (0)
In vitro antibacterial activity and beta-lactamase stability of CL 118523, an aminothiazolyl iminomethoxy cephalosporin. (1987) (0)
INFECTIONS IN INTE NSIVE CARE PATIENTS: USE OF NEW B-LACTAMS* (2006) (0)
Outbreak of aspergillus in heart transplant patients (1990) (0)
Use of Fluoroquinolone Antimicrobial Agents by Cardiovascular and Cardiopulmonary Surgeons (0)
Antibiotic Ciprofloxacin Amoxicillin Ciprofloxacin Norfloxacin Cephalexin Amoxicillin Ciprofloxacin Ciprofloxacin Amoxicillin Ciprofloxacin Norfloxacin Ceftazidime Cephalexin Amoxicillin Trimethoprim Ciprofloxacin Norfloxacin Cephalexin Amoxicillin Trimethoprim Ciprofloxacin Norfloxacin Cefotaxime (2003) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Harold C. Neu?

Harold C. Neu is affiliated with the following schools:

Columbia University

Harold C. Neu's Academic­Influence.com Rankings

Harold C. Neu's Degrees

Why Is Harold C. Neu Influential?

Harold C. Neu's Published Works

Published Works

What Schools Are Affiliated With Harold C. Neu?

Harold C. Neu's AcademicInfluence.com Rankings